Which manufacturer produces zolbetuximab and what is its quality?

Zolbetuximab (zolbetuximab) is launched under the trade name Vyloy and is developed and produced by Astellas Pharma, an internationally renowned pharmaceutical company. This company has strong R&D capabilities in the field of global oncology drugs, especially in antibody drugs and precision targeted therapy for many years, allowing Vyloy to follow strict international standards from early research to commercialization. Astellas has biologics production lines in many places in Europe, America and Asia, all of which have passed standardized quality review systems to ensure the stability, purity and controllability of protein drugs. This type of monoclonal antibody has extremely high requirements on the production process, and a slight deviation can affect the active structure. Therefore, the quality control system adopted by the company is particularly important.

The core technology of zotuximab is based on targeting CLDN18.2 protein, which is a marker ofgastric cancer and gastroesophageal junction cancer that has attracted international attention in recent years. Since this target has limited expression in normal tissues, it has high theoretical selectivity for precision tumor treatment. Astellas uses a purified cell culture system and stable strain construction technology in the production of zotuximab, which makes it easier to maintain the integrity of the antibody structure and reduce degradation during storage or transportation. These production processes have undergone multiple rounds of verification to ensure the consistency of drug ingredients, which also enables different batches of drugs to perform stably in clinical applications.

In addition, the approval process for zotuximab involved strict review by drug regulatory agencies in many places, especially in the key aspects of immunogenicity, purity control, impurity testing and toxicology data review in biological preparations. Although specific clinical figures cannot be quoted, public regulatory information can confirm that it meets international quality standards, including the regulatory requirements common to FDA, EMA and other regions.

Reference materials:https://www.astellas.com/en/news/29401